Bruno, Canada). to 33-flip higher EC50 for ruxolitinib in comparison to indigenous JAK2V617F. Our outcomes additional indicated these mutations conferred cross-resistance to all or any
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor